UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  April 18, 2013

 

EXACT SCIENCES CORPORATION

(Exact Name of Registrant as Specified in Charter)

 

Delaware

 

000-32179

 

02-0478229

(State or Other Jurisdiction
of Incorporation)

 

(Commission
File Number)

 

(I.R.S. Employer
Identification No.)

 

441 Charmany Drive
Madison, WI 53719

(Address of Principal Executive Offices)(Zip Code)

 

Registrant’s telephone number, including area code:  (608) 284-5700

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

7.01.                     Regulation FD Disclosure.

 

On April 18, 2013, Exact Sciences Corporation (the “Company”) issued a press release reporting preliminary top-line data from the DeeP-C clinical trial for the Company’s Cologuard colorectal cancer screening test.

 

A copy of the press release is furnished as Exhibit 99 to this Current Report and is incorporated herein by reference.

 

9.01.       Financial Statements and Exhibits.

 

Exhibits

 

The exhibits required to be filed as a part of this Current Report on Form 8-K are listed in the Exhibit Index attached hereto and incorporated herein by reference.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

EXACT SCIENCES CORPORATION

 

 

Date: April 18, 2013

By:

/s/ Maneesh Arora

 

 

Maneesh Arora

 

 

Chief Operating Officer

 

3


 

EXHIBIT INDEX

 

Exhibit No.

 

Exhibit Description

 

 

 

99

 

Press release, dated April 18, 2013, issued by Exact Sciences Corporation, furnished herewith

 

4